Organogenesis Revenue Fell 58% After a CMS Reimbursement Change Gutted Its Wound-Care Business

Organogenesis reported second-quarter 2026 net revenue of $42.8 million, down $58.0 million — a 58% decline — from $100.8 million in the same quarter a year earlier. The collapse was concentrated in the company's largest product line: Advanced Wound Care revenue fell 61% year over year to $36.1 million. Surgical & Sports Medicine revenue, the smaller segment, declined a more modest 18% to $6.7 million.

The cause is regulatory, not competitive or demand-driven: a CMS and Medicare reimbursement policy change disrupted the wound-care market Organogenesis primarily serves. When a reimbursement change of this scale hits a company's core segment specifically — Advanced Wound Care fell more than three times as hard as Surgical & Sports Medicine — it signals the policy change targeted the specific billing codes or coverage categories tied to that product line, rather than reflecting a broader slowdown across the company's whole business.

The bottom-line impact was severe: net loss widened to $96.3 million from $9.4 million in the same quarter last year — a company that was modestly unprofitable a year ago posted a loss roughly ten times larger on the reimbursement-driven revenue collapse.

What makes this more than a single bad quarter is the guidance: Organogenesis's full-year 2026 revenue outlook is $270 million to $310 million, representing a 45% to 52% year-over-year decline. Guidance implying a decline of that magnitude across the full year, not just the reported quarter, tells investors management does not expect the reimbursement disruption to resolve quickly — it is being treated as a structural change to the business's near-term revenue base, not a temporary shock the company expects to recover from within the year.